Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives.

Dos Santos JL, Lanaro C, Chelucci RC, Gambero S, Bosquesi PL, Reis JS, Lima LM, Cerecetto H, González M, Costa FF, Chung MC.

J Med Chem. 2012 Sep 13;55(17):7583-92. doi: 10.1021/jm300602n. Epub 2012 Aug 21.

PMID:
22889416
2.

Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.

dos Santos JL, Lanaro C, Lima LM, Gambero S, Franco-Penteado CF, Alexandre-Moreira MS, Wade M, Yerigenahally S, Kutlar A, Meiler SE, Costa FF, Chung M.

J Med Chem. 2011 Aug 25;54(16):5811-9. doi: 10.1021/jm200531f. Epub 2011 Jul 25.

PMID:
21766854
4.

Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors.

Mu L, Feng SS, Go ML.

Chem Pharm Bull (Tokyo). 2000 Jun;48(6):808-16.

PMID:
10866141
5.

Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.

Ling Y, Ye X, Zhang Z, Zhang Y, Lai Y, Ji H, Peng S, Tian J.

J Med Chem. 2011 May 12;54(9):3251-9. doi: 10.1021/jm1014814. Epub 2011 Apr 19.

PMID:
21504204
7.

Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization.

López GV, Blanco F, Hernández P, Ferreira A, Piro OE, Batthyány C, González M, Rubbo H, Cerecetto H.

Bioorg Med Chem. 2007 Sep 15;15(18):6262-72. Epub 2007 Jun 13.

PMID:
17627828
8.

Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.

Buonsanti MF, Bertinaria M, Stilo AD, Cena C, Fruttero R, Gasco A.

J Med Chem. 2007 Oct 4;50(20):5003-11. Epub 2007 Sep 11.

PMID:
17845020
9.

Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.

Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF.

Haematologica. 2008 Apr;93(4):605-9. doi: 10.3324/haematol.12119. Epub 2008 Mar 6.

10.

Design, synthesis and in vitro NO-releasing activities of ocotillol-type furoxans.

Bi Y, Yang J, Ma C, Liu ZY, Zhang TT, Zhang XC, Lu J, Meng QG.

Pharmazie. 2015 Apr;70(4):213-8.

PMID:
26012249
11.

Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.

Fernandes GF, de Souza PC, Marino LB, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Chung MC, Pavan FR, Dos Santos JL.

Eur J Med Chem. 2016 Nov 10;123:523-31. doi: 10.1016/j.ejmech.2016.07.039. Epub 2016 Jul 21.

PMID:
27508879
12.

Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.

Li D, Wang L, Cai H, Zhang Y, Xu J.

Molecules. 2012 Jun 18;17(6):7556-68. doi: 10.3390/molecules17067556.

13.

New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities.

Di Stilo A, Visentin S, Cena C, Gasco AM, Ermondi G, Gasco A.

J Med Chem. 1998 Dec 31;41(27):5393-401.

PMID:
9876109
14.

Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: synthesis and their anti-inflammatory and analgesic activities.

Akhter M, Husain A, Azad B, Ajmal M.

Eur J Med Chem. 2009 Jun;44(6):2372-8. doi: 10.1016/j.ejmech.2008.09.005. Epub 2008 Sep 16.

PMID:
18977556
15.

The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.

Del Grosso E, Boschi D, Lazzarato L, Cena C, Di Stilo A, Fruttero R, Moro S, Gasco A.

Chem Biodivers. 2005 Jul;2(7):886-900.

PMID:
17193179
16.

Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.

Gladwin MT, Shelhamer JH, Ognibene FP, Pease-Fye ME, Nichols JS, Link B, Patel DB, Jankowski MA, Pannell LK, Schechter AN, Rodgers GP.

Br J Haematol. 2002 Feb;116(2):436-44.

PMID:
11841449
17.

New potential uroselective NO-donor alpha1-antagonists.

Boschi D, Tron GC, Di Stilo A, Fruttero R, Gasco A, Poggesi E, Motta G, Leonardi A.

J Med Chem. 2003 Aug 14;46(17):3762-5.

PMID:
12904082
18.

Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety.

Fang L, Zhang Y, Lehmann J, Wang Y, Ji H, Ding D.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):1062-6. Epub 2006 Nov 10.

PMID:
17129724
19.

Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives.

Hernández P, Cabrera M, Lavaggi ML, Celano L, Tiscornia I, Rodrigues da Costa T, Thomson L, Bollati-Fogolín M, Miranda AL, Lima LM, Barreiro EJ, González M, Cerecetto H.

Bioorg Med Chem. 2012 Mar 15;20(6):2158-71. doi: 10.1016/j.bmc.2012.01.034. Epub 2012 Feb 2.

PMID:
22356737
20.

Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans.

Lazzarato L, Cena C, Rolando B, Marini E, Lolli ML, Guglielmo S, Guaita E, Morini G, Coruzzi G, Fruttero R, Gasco A.

Bioorg Med Chem. 2011 Oct 1;19(19):5852-60. doi: 10.1016/j.bmc.2011.08.018. Epub 2011 Aug 16.

PMID:
21906954

Supplemental Content

Support Center